An Early Phase 1 interventional study of Picato in Molluscum Contagiosum, sponsored by Center for Clinical Studies, Texas. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by Center for Clinical Studies, Texas · Early Phase 1, Interventional, and Treatment
Among 15 studies in Molluscum Contagiosum with a site in United States — none open to participants now, none under way, none of them phase 3. Molluscum Contagiosum · United States.
Among the 15 studies in Molluscum Contagiosum with a site in United States, this one is the 14th largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1, and was the 7th registered.
22 studies on the registry are indexed under Molluscum Contagiosum; none are open to participants now.
Browse Molluscum Contagiosum studies →None of the 15 studies in Molluscum Contagiosum with a site in United States is open now. The open studies under Molluscum Contagiosum, anywhere →
This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2017.
Median enrollment 100 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 10 most frequent:
Center for Clinical Studies, Texas is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Center for Clinical Studies, Texas has 1 study filed under Molluscum Contagiosum — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Molluscum Contagiosum with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients at least 18 years of age will be enrolled in the study to assess the efficacy and tolerability of Picato gel in the treatment of molluscum contagiosum. Patients must have an immunocompromised condition due to taking immunosuppressive drugs or having an inherited disease affecting the immune system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has at least 10 clinically typical, visible and discrete MCs within a treatment area on either the face and/or trunk. Treatment area is defined as either:
Exclusion Criteria:
Location of the treatment area
Receipt of the following within 90 days prior to study treatment initiation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Picato
Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
Complete clearance at Week 4
Complete clearance is defined as no clinically visible MCs in the treatment area/
Time frame: 4 weeks
Partial clearance at Week 4
Partial clearance defined as at least 50% reduction in the number of clinically visible MCs in the treatment area.
Time frame: 4 weeks
Percentage of subjects who sustain complete clearance of MCs in the treatment area at Week 24
Time frame: 24 weeks
Percentage of subjects who clear MCs outside of the treatment area at Week 24
Time frame: 24 weeks
Treatment Satisfaction Questionnaire for Medication
Scale range from "extremely satisfied" to "extremely dissatisfied".
Time frame: 24 weeks
EQ-5D-5L Index and Health Status
Scale range from 0 (worst health) to 100 (best health).
Time frame: 24 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Sep 2018, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ingenol mebutate
Center for Clinical Studies, Texas